Akcea Therapeutics, Inc. (AKCA) Financial Statements (2023 and earlier)

Company Profile

Business Address 22 BOSTON WHARF RD
BOSTON, MA 02210
State of Incorp. DE
Fiscal Year End December 31
Industry (SIC) 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) ($ in thousands)

12/31/2019
12/31/2018
12/31/2017
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments, including:252,600260,130
Cash and cash equivalents86,45458,367
Short-term investments166,155201,763
Other undisclosed cash, cash equivalents, and short-term investments(9) 
Receivables4,5975,413
Inventory, net of allowances, customer advances and progress billings  
Inventory  
Contract with customer, asset, after allowance for credit loss 
Other current assets10,0291,302
Other undisclosed current assets9 
Total current assets:267,235266,845
Noncurrent Assets
Operating lease, right-of-use asset
Property, plant and equipment5,69677
Intangible assets, net (including goodwill)88,9141,221
Intangible assets, net (excluding goodwill)88,9141,221
Other noncurrent assets3,416661
Total noncurrent assets:98,0261,959
TOTAL ASSETS:365,261268,804
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities35,43814,034
Employee-related liabilities8,5834,083
Accounts payable12,0682,381
Accrued liabilities14,7877,570
Deferred revenue
Deferred revenue and credits50,579
Due to related parties 18,90114,365
Contract with customer, liability25,354
Other liabilities9681,875
Total current liabilities:80,66180,853
Noncurrent Liabilities
Long-term debt and lease obligation:  
Liabilities, other than long-term debt 7,8768,318
Deferred revenue and credits8,318
Contract with customer, liability3,434
Deferred rent credit 4,442
Operating lease, liability
Total noncurrent liabilities:7,8768,318
Total liabilities:88,53789,171
Equity
Equity, attributable to parent276,724179,633
Common stock8967
Additional paid in capital799,001464,430
Accumulated other comprehensive income (loss)(324)(451)
Accumulated deficit(522,042)(284,413)
Total equity:276,724179,633
TOTAL LIABILITIES AND EQUITY:365,261268,804

Income Statement (P&L) ($ in thousands)

12/31/2019
12/31/2018
12/31/2017
Revenues64,86755,209
Cost of revenue
(Cost of Goods and Services Sold)
 (2,713) 
Gross profit:62,15455,209
Operating expenses(295,683)(163,871)
Other undisclosed operating income2,713 
Operating income (loss):(230,816)(108,662)
Nonoperating income5,4421,917
Investment income, nonoperating5,6311,813
Interest and debt expense  (1,731)
Income (loss) from continuing operations before income taxes:(225,374)(108,476)
Income tax expense(447)(1,275)
Income (loss) from continuing operations:(225,821)(109,751)
Income (loss) before gain (loss) on sale of properties:(225,821)(109,751)
Net income (loss) attributable to parent:(225,821)(109,751)
Preferred stock dividends and other adjustments  (20,100)
Other undisclosed net loss available to common stockholders, basic(7,792) 
Net income (loss) available to common stockholders, diluted:(233,613)(129,851)

Comprehensive Income ($ in thousands)

12/31/2019
12/31/2018
12/31/2017
Net income (loss):(225,821)(109,751)
Comprehensive income (loss):(225,821)(109,751)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent127(430)
Comprehensive income (loss), net of tax, attributable to parent:(225,694)(110,181)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: